Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators

BACKGROUND AND AIMS: GS‐9688 (selgantolimod) is a toll‐like receptor 8 agonist in clinical development for the treatment of chronic hepatitis B (CHB). Antiviral activity of GS‐9688 has previously been evaluated in vitro in HBV‐infected hepatocytes and in vivo in the woodchuck model of CHB. Here we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Oliver E., Colbeck, Emily J., Daffis, Stephane, Khan, Shahzada, Ramakrishnan, Dhivya, Pattabiraman, Divya, Chu, Ruth, Micolochick Steuer, Holly, Lehar, Sophie, Peiser, Leanne, Palazzo, Adam, Frey, Christian, Davies, Jessica, Javanbakht, Hassan, Rosenberg, William M.C., Fletcher, Simon P., Maini, Mala K., Pallett, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436741/
https://www.ncbi.nlm.nih.gov/pubmed/33368377
http://dx.doi.org/10.1002/hep.31695

Ejemplares similares

Ejemplares similares